Sunday – June 15th, 2025
Symposium Day 3
|
Symposium XIII: Cancer-Associated Thrombosis: A Silent Killer
Breaking the Silence on Prevention Moderator: Prof. dr. Catharina Suharti, PhD, SpPD-KHOM |
|
| 08.00 – 08.20 |
From Awareness to Understanding: The Complexity of Cancer Associated Thrombosis
Speaker: Clinical Prof Ng Heng Joo, MBBS, M.Med, MRCP, FRC Path, FAMS
|
| 08.20 – 08.40 |
Preventing Thrombosis in Cancer Patients: Strategies for Safer Oncology Care
Speaker: Dr. dr. Budi Setiawan, SpPD-KHOM
|
| 08.40 – 08.50 | Discussion |
|
Meet the Expert: Risk Stratification Discussion
Based on Evolving Evidence in Management of Luminal HER2-Negative Early Breast Cancer Moderator: dr. Nadia Mulansari, SpPD-KHOM |
|
| 08.50 – 09.10 |
Case Presentation
Understanding Risk of Recurrence in Node-Positive PatientsDr. dr. Shinta O. Wardhani, SpPD-KHOM
Understanding Risk of Recurrence in Node-Negative PatientsDr. dr. Jeffry Beta Tenggara, SpPD-KHOM
|
| 09.10 – 09.50 |
Panel Discussion
Dr. Joline Lim, MBBS, MRCP, M.Med, FAMS
Dr. dr. Eko Adhi Pangarsa, SpPD-KHOM Dr. dr. Kartika Widayati, SpPD-KHOM |
|
Symposium XIV: Beyond Standard Care
Innovating Treatment Strategies for Luminal HER2-Negative Metastatic Breast Cancer Moderator: Dr. dr. Tubagus Djumhana Atmakusuma, SpPD-KHOM |
|
| 09.50 – 10.10 |
Understanding the Biology of HR-Positive, HER2-Negative Metastatic Breast Cancer: Mechanisms, Progression, and Treatment Challenges
Speaker: dr. Nadia Ayu Mulansari, SpPD-KHOM
|
| 10.10 – 10.30 |
Optimizing the Role of CDK 4/6 inhibitor for Metastatic Breast Cancer patient in Accordance with P-VERIFY RWE
Speaker: Dr. dr. Kartika Widayati, SpPD-KHOM
|
| 10.30 – 10.40 | Discussion |
|
Symposium XV: Transforming Lung Cancer Treatment
The Path to Precision Therapy as Standard Care Moderator: Dr. dr. Andhika Rachman, SpPD-KHOM |
|
| 10.40 – 11.00 |
Treat Right from the Start: Elevating Patient Outcomes through First-Line Practice in NSCLC (Non-Driven Mutation)
Speaker: Dr. dr. Indra Wijaya, SpPD-KHOM
|
| 11.00 – 11.20 |
Strategies for Precision Therapy as Standard of Care in Small Cell Lung Cancer
Speaker: Dr. dr. Budi Setiawan, SpPD-KHOM
|
| 11.20 – 11.30 | Discussion |
| Symposium XVI: Recent Advances in anti PD-1 Monoclonal Antibody for Lung Cancer Moderator: dr. Mediarty Syahrir, SpPD-KHOM | |
| 11.30 – 11.50 |
The Role of Immunotherapy in the Treatment of First-line ES-SCLC
Speaker: Dr. dr. Shinta Oktya Wardhani, SpPD-KHOM
|
| 11.50 – 12.10 |
An Update of Immunotherapy for SQ-NSLC: The Role of PD-1 Inhibitor
Speaker: Dr. dr. Eko Adhi Pangarsa, SpPD-KHOM
|
| 12.10 – 12.20 | Discussion |
|
Lunch Symposium II: Multidisciplinary Innovations in HCC Management
Integrating Locoregional and Systemic Therapies Moderator: Dr. dr. Jeffry Betta Tenggara, SpPD-KHOM Dr. dr. Hery Djagat Purnomo, Sp.PD-KGEH |
|
| 12.20 – 12.40 |
Putting It Together: Multidisciplinary Care Programs for Patients with HCC, A Hepatologist’s Perspective
Speaker: Prof. Ya Bing Guo, MD
|
| 12.40 – 13.00 |
Rethinking Liver Cancer Management: A New Path Forward
Speaker: dr. Daniel Rizky, Sp.PD-KHOM
|
| 13.00 – 13.20 |
Unveiling the Key Factors: Critical Aspects in Intermediate-Stage HCC Treatment Today
Speaker: Dr. Choo Su Pin, BMedSci, BMBS, MRCP, FAMS
|
| 13.20 – 13.30 | Discussion |
| 13.30 – 14.00 |
Closing Remarks
|
